Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: A survey of the childhood arthritis and rheumatology research alliance

Journal of Rheumatology

Volumn 44, Issue 3, 2017, Pages 352-360

  Horton, Daniel B ^a   Onel, Karen B ^b   Beukelman, Timothy ^c   Ringold, Sarah ^d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical decision making; Clinical inactive disease; Juvenile idiopathic arthritis; Pediatric rheumatic diseases

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT;

ADVERSE DRUG REACTION; BONE EROSION; CHILD; CLINICAL DECISION MAKING; DISEASE ACTIVITY; DISEASE DURATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; JOINT DESTRUCTION; JUVENILE RHEUMATOID ARTHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT PREFERENCE; PHYSICIAN ATTITUDE; POLYARTHRITIS; REVIEW; RHEUMATOLOGIST; SACROILIAC JOINT; TEMPOROMANDIBULAR JOINT DISORDER; FEMALE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; MALE; REMISSION; RHEUMATOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; ATTITUDE OF HEALTH PERSONNEL; CHILD; CLINICAL DECISION-MAKING; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; METHOTREXATE; REMISSION INDUCTION; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 85016398838     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.161078     Document Type: Review

References (25)

1. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74:1854-60.
2. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al; Childhood Arthritis and Rheumatology Research Alliance. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
3. Consolaro A, Ravelli A. It is worth including assessment of disease activity state in juvenile arthritis clinical trials. Arthritis Care Res 2013;65:1207-10.
4. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929-36.
5. Prince FH, Twilt M, Simon SC, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:1228-9.
6. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al; Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: A randomized clinical trial. JAMA 2010;303:1266-73.
7. Remesal A, De Inocencio J, Merino R, Garcia-Consuegra J. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol 2010;37:1970-1.
8. Baszis K, Garbutt J, Toib D, Mao J, King A, White A, et al. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: A twelve-year experience. Arthritis Rheum 2011;63:3163-8.
9. Cai Y, Liu X, Zhang W, Xu J, Cao L. Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission. Rheumatol Int 2013;33:2277-82.
10. Postȩpski J, Kobusińska K, Olesińska E, Osińska V, Opoka-Winiarska V. Clinical remission in juvenile idiopathic arthritis after termination of etanercept. Rheumatol Int 2013;33:2657-60.
11. Chang CY, Meyer RM, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res 2015;67:658-66.
12. Iglesias E, Torrente-Segarra V, Bou R, Ricart S, González MI, Sanchez J, et al. Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: A clinical practice observational study of patients who discontinued treatment. Rheumatol Int 2014;34:1053-7.
13. Guzman J, Oen K, Huber AM, Watanabe Duffy K, Boire G, Shiff N, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis 2016;75:1092-8.
14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-81.
15. Watson R. Publishing the results of factor analysis: interpretation and presentation. J Adv Nurs 1998;28:1361-3.
16. Johnson TP, Wislar JS. Response rates and nonresponse errors in surveys. JAMA 2012;307:1805-6.
17. Broughton T, Armon K. Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus. Paediatr Drugs 2012;14:7-12.
18. Davies R, Carrasco R, Foster HE, Baildam EM, Chieng SE, Davidson JE, et al. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum 2016;46:190-5.
19. Beukelman T, Ringold S, Davis TE, DeWitt EM, Pelajo CF, Weiss PF, et al; CARRA Registry Investigators. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA Registry. J Rheumatol 2012;39:1867-74.
20. Rebollo-Polo M, Koujok K, Weisser C, Jurencak R, Bruns A, Roth J. Ultrasound findings on patients with juvenile idiopathic arthritis in clinical remission. Arthritis Care Res 2011;63:1013-9.
21. Hemke R, Maas M, van Veenendaal M, Dolman KM, van Rossum MA, van den Berg JM, et al. Contrast-enhanced MRI compared with the physical examination in the evaluation of disease activity in juvenile idiopathic arthritis. Eur Radiol 2014;24:327-34.
22. Bugni Miotto e Silva V, de Freitas Tavares da Silva C, de Aguiar Vilela Mitraud S, Nely Vilar Furtado R, Esteves Hilário MO, Natour J, et al. Do patients with juvenile idiopathic arthritis in remission exhibit active synovitis on joint ultrasound? Rheumatol Int 2014;34:937-45.
23. Colebatch-Bourn AN, Edwards CJ, Collado P, D'Agostino MA, Hemke R, Jousse-Joulin S, et al. EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Ann Rheum Dis 2015;74:1946-57.
24. Chauvin NA, Khwaja A. Imaging of inflammatory arthritis in children: status and perspectives on the use of ultrasound, radiographs, and magnetic resonance imaging. Rheum Dis Clin North Am 2016;42:587-606.
25. Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: A comparative study. Ann Rheum Dis 2012;71:1991-7.